Difference between revisions of "Amifostine (Ethyol)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>")
(updated content)
Line 1: Line 1:
 
==General information==
 
==General information==
Class/mechanism: prodrug of a free thiol metabolite, converted to the active form by alkaline phosphatase, that reduces the cumulative renal toxicity of cisplatin and oral toxicity of radiation by scavaging reactive metabolites and reactive oxygen species.  Amifostine is thought to preferentially protect normal tissues because they have higher alkaline phosphatase activity, higher pH, and better vascularity.<ref name="insert">[http://www.ethyol.com/ Amifostine (Ethyol) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/amifostine.pdf Amifostine (Ethyol) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Prodrug of a free thiol metabolite, converted to the active form by alkaline phosphatase, that reduces the cumulative renal toxicity of cisplatin and oral toxicity of radiation by scavaging reactive metabolites and reactive oxygen species.  Amifostine is thought to preferentially protect normal tissues because they have higher alkaline phosphatase activity, higher pH, and better vascularity.<ref name="insert">[http://www.ethyol.com/ Amifostine (Ethyol) package insert]</ref><ref>[[Media:Amifostine.pdf | Amifostine (Ethyol) package insert (locally hosted backup)]]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: no information
 
<br>Extravasation: no information
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
 +
 +
==Diseases for which it is used==
 +
*[[Bone cancer]]
  
 
==Patient drug information==
 
==Patient drug information==
*[http://www.chemocare.com/bio/amifostine.asp Amifostine (Ethyol) patient drug information (Chemocare)]<ref>[http://www.chemocare.com/bio/amifostine.asp Amifostine (Ethyol) patient drug information (Chemocare)]</ref>
+
*[http://chemocare.com/chemotherapy/drug-info/amifostine.aspx Amifostine (Ethyol) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/amifostine.aspx Amifostine (Ethyol) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/amifostine-patient-drug-information Amifostine (Ethyol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/amifostine-patient-drug-information Amifostine (Ethyol) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/amifostine-patient-drug-information Amifostine (Ethyol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/amifostine-patient-drug-information Amifostine (Ethyol) patient drug information (UpToDate)]</ref>
  
 
==References==
 
==References==
 
<references/>
 
<references/>

Revision as of 02:13, 7 October 2012

General information

Class/mechanism: Prodrug of a free thiol metabolite, converted to the active form by alkaline phosphatase, that reduces the cumulative renal toxicity of cisplatin and oral toxicity of radiation by scavaging reactive metabolites and reactive oxygen species. Amifostine is thought to preferentially protect normal tissues because they have higher alkaline phosphatase activity, higher pH, and better vascularity.[1][2]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

References